Microbiota and diabetes: an evolving relationship
- PMID: 24833634
- DOI: 10.1136/gutjnl-2014-306928
Microbiota and diabetes: an evolving relationship
Abstract
The gut microbiota affects numerous biological functions throughout the body and its characterisation has become a major research area in biomedicine. Recent studies have suggested that gut bacteria play a fundamental role in diseases such as obesity, diabetes and cardiovascular disease. Data are accumulating in animal models and humans suggesting that obesity and type 2 diabetes (T2D) are associated with a profound dysbiosis. First human metagenome-wide association studies demonstrated highly significant correlations of specific intestinal bacteria, certain bacterial genes and respective metabolic pathways with T2D. Importantly, especially butyrate-producing bacteria such as Roseburia intestinalis and Faecalibacterium prausnitzii concentrations were lower in T2D subjects. This supports the increasing evidence, that butyrate and other short-chain fatty acids are able to exert profound immunometabolic effects. Endotoxaemia, most likely gut-derived has also been observed in patients with metabolic syndrome and T2D and might play a key role in metabolic inflammation. A further hint towards an association between microbiota and T2D has been derived from studies in pregnancy showing that major gut microbial shifts occurring during pregnancy affect host metabolism. Interestingly, certain antidiabetic drugs such as metformin also interfere with the intestinal microbiota. Specific members of the microbiota such as Akkermansia muciniphila might be decreased in diabetes and when administered to murines exerted antidiabetic effects. Therefore, as a 'gut signature' becomes more evident in T2D, a better understanding of the role of the microbiota in diabetes might provide new aspects regarding its pathophysiological relevance and pave the way for new therapeutic principles.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Similar articles
-
[Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].Orv Hetil. 2016 Jan 3;157(1):13-22. doi: 10.1556/650.2015.30296. Orv Hetil. 2016. PMID: 26708682 Review. Hungarian.
-
Glucose metabolism: focus on gut microbiota, the endocannabinoid system and beyond.Diabetes Metab. 2014 Sep;40(4):246-57. doi: 10.1016/j.diabet.2014.02.004. Epub 2014 Mar 14. Diabetes Metab. 2014. PMID: 24631413 Review.
-
An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice.Gut. 2014 May;63(5):727-35. doi: 10.1136/gutjnl-2012-303839. Epub 2013 Jun 26. Gut. 2014. PMID: 23804561
-
Gut microbiota and metabolic syndrome.World J Gastroenterol. 2014 Nov 21;20(43):16079-94. doi: 10.3748/wjg.v20.i43.16079. World J Gastroenterol. 2014. PMID: 25473159 Free PMC article. Review.
-
Obesity, metabolic syndrome, and microbiota: multiple interactions.J Clin Gastroenterol. 2010 Sep;44 Suppl 1:S16-8. doi: 10.1097/MCG.0b013e3181dd8b64. J Clin Gastroenterol. 2010. PMID: 20535027
Cited by
-
Application of metagenomics in the human gut microbiome.World J Gastroenterol. 2015 Jan 21;21(3):803-14. doi: 10.3748/wjg.v21.i3.803. World J Gastroenterol. 2015. PMID: 25624713 Free PMC article. Review.
-
Manipulating the gut microbiota to maintain health and treat disease.Microb Ecol Health Dis. 2015 Feb 2;26:25877. doi: 10.3402/mehd.v26.25877. eCollection 2015. Microb Ecol Health Dis. 2015. PMID: 25651995 Free PMC article.
-
Application of Dominant Gut Microbiota Promises to Replace Fecal Microbiota Transplantation as a New Treatment for Alzheimer's Disease.Microorganisms. 2023 Nov 24;11(12):2854. doi: 10.3390/microorganisms11122854. Microorganisms. 2023. PMID: 38137998 Free PMC article.
-
Antibiotic use during pregnancy: how bad is it?BMC Med. 2016 Jun 17;14(1):91. doi: 10.1186/s12916-016-0636-0. BMC Med. 2016. PMID: 27312712 Free PMC article.
-
Anti-TNF-α therapy alters the gut microbiota in proteoglycan-induced ankylosing spondylitis in mice.Microbiologyopen. 2019 Dec;8(12):e927. doi: 10.1002/mbo3.927. Epub 2019 Sep 26. Microbiologyopen. 2019. PMID: 31556231 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical